MindMed gains af­ter in­ves­ti­ga­tor tri­al of LSD shows im­pact on ma­jor de­pres­sion

Shares of MindMed surged Fri­day morn­ing af­ter re­searchers who have worked with the com­pa­ny un­veiled pos­i­tive re­sults in a tri­al us­ing LSD to treat ma­jor de­pres­sive dis­or­der, run­ning a test sim­i­lar to the biotech’s tri­als of its own re­lat­ed com­pound.

The Swiss in­ves­ti­ga­tors at the Uni­ver­si­ty Hos­pi­tal Basel and the Uni­ver­si­ty Hos­pi­tal of Psy­chi­a­try treat­ed 28 pa­tients with a high dose of LSD, while 27 pa­tients re­ceived a much low­er ac­tive con­trol dose. Pa­tients were mea­sured us­ing the In­ven­to­ry of De­pres­sive Symp­to­ma­tol­ogy sys­tem, which scores de­pres­sion based on a score of ze­ro to 84.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER